IP Library Granted Patent US 10,004,695
Granted Patent B2
US 10,004,695 · App. 15/304,127 · Granted Jun 26, 2018

GM3 functionalized nanoparticles

Inventors: Bjoern Markus Reinhard (Brookline, MA); Suryaram Gummuluru (Westwood, MA)
Assignee: Trustees of Boston University
A61K9/5123A61B5/055A61K9/127A61K9/1271A61K9/1272A61K9/5115A61K9/5192A61K47/4823A61K47/48046A61K47/48815A61K47/48861A61K47/48884B82Y5/00G01N33/5005
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,004,695
App. No.
15/304,127
Granted
Jun 26, 2018
Kind
B2
Abstract

Embodiments disclosed herein relates to ganglioside GM3-containing mixed lipids nanoparticles having an overall size between 60-100 nm, the making thereof and the uses. The nanoparticles selectively targeted to CD169+ expressing cells such as dendritic cells and macrophage. The nanoparticles are endocytosed by the CD169+ expressing cells.

Claims (14)

1. A nanoparticle comprising:

a) a core having a largest diameter between 50-90 nm;

b) a coating layer encasing the core, wherein the core comprises a material selected from the group consisting of gold, silver, a gold alloy, a silver alloy, silica, mesoporous silica, polystyrene, and titania; and

c) a ganglioside GM3-containing mixed lipid layer comprising of dipalmitoylphosphatidylcholine (DPPC), cholesterol, phosphatidylserine (PS), and aNeu5Ac(2-3)bDGalp(1-4)bDG1cp(1-1)Cer (GM3); wherein the ganglioside GM3-mixed lipid layer is exterior of the coating layer and is integrated into the coating layer, and wherein the nanoparticles have an overall particle size between 60-100 nm.

2. The nanoparticle of claim 1 , wherein the core is a solid core.

3. The nanoparticle of claim 1 , wherein the core has a shape that is selected from the group consisting of ellipsoid, spherical, rod-like, octahedral, and cube-like.

4. The nanoparticle of claim 1 , wherein the coating layer is a thiolated lipid, a silane with long alkyl chains, or polyethylene glycol thiol.

5. The nanoparticle of claim 1 , wherein the ganglioside GM3 containing mixed lipid layer consists of 40%-60% of DPPC.

6. The nanoparticle of claim 1 , wherein the ganglioside GM3 containing mixed lipid layer consists of 40%-60% of cholesterol.

7. The nanoparticle of claim 1 , wherein the ganglioside GM3 containing mixed lipid layer consists of 0.5%-5% of PS.

8. The nanoparticle of claim 1 , wherein the ganglioside GM3 containing mixed lipid layer consists of 0.1%-6% of GM3.

9. The nanoparticle of claim 1 , wherein the ganglioside GM3 containing mixed lipid layer optionally consist of galactosylceramide (Gal-Cer).

10. The nanoparticle of claim 1 , wherein the ganglioside GM3 containing mixed lipid layer consists of DPPC, cholesterol, PS, and GM3, and optionally Gal-Cer.

11. The nanoparticle of claim 1 , wherein the nanoparticle comprises a second layer of ganglioside GM3 containing mixed lipid.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 16, 2018
From: BOSTON UNIVERSITY CHARLES RIVER CAMPUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046555/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2017
From: REINHARD, BJOERN MARKUS; GUMMULURU, SURYARAM
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 043647/0869 →
Continuity (2)
Provisional Application 61980175 · Apr 16, 2014
Related Publication 20170042824A1 · Feb 16, 2017